Firas Badin

3.0k total citations
21 papers, 201 citations indexed

About

Firas Badin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Firas Badin has authored 21 papers receiving a total of 201 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Firas Badin's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (8 papers). Firas Badin is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (8 papers). Firas Badin collaborates with scholars based in United States, Canada and Spain. Firas Badin's co-authors include Enriqueta Felip, Luis Paz‐Ares, Martin Reck, Neal Ready, Rosalyn A. Juergens, Solange Peters, Suresh Nair, Mark A. Socinski, Ben Creelan and Michel M. van den Heuvel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Firas Badin

20 papers receiving 196 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Firas Badin United States 6 152 112 43 40 26 21 201
Marie Naigeon France 9 163 1.1× 86 0.8× 34 0.8× 78 1.9× 26 1.0× 21 212
Mohammad Atiq United States 6 88 0.6× 64 0.6× 54 1.3× 49 1.2× 26 1.0× 21 155
W. Victoria Lai United States 4 107 0.7× 87 0.8× 41 1.0× 34 0.8× 18 0.7× 5 172
Grygorii Ursol United Kingdom 4 233 1.5× 143 1.3× 27 0.6× 54 1.4× 24 0.9× 6 268
Avi Spira United States 3 121 0.8× 63 0.6× 72 1.7× 76 1.9× 59 2.3× 7 202
Deepti Venkatraman United States 5 126 0.8× 82 0.7× 49 1.1× 23 0.6× 30 1.2× 10 169
Xu-Shan Sun France 7 124 0.8× 80 0.7× 36 0.8× 31 0.8× 22 0.8× 13 193
David Vicente Baz Spain 10 173 1.1× 138 1.2× 52 1.2× 40 1.0× 29 1.1× 27 235
Andrés Aguilar Spain 7 97 0.6× 102 0.9× 120 2.8× 22 0.6× 63 2.4× 17 209
H.Z. Turna Türkiye 7 326 2.1× 264 2.4× 48 1.1× 50 1.3× 50 1.9× 8 367

Countries citing papers authored by Firas Badin

Since Specialization
Citations

This map shows the geographic impact of Firas Badin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Firas Badin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Firas Badin more than expected).

Fields of papers citing papers by Firas Badin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Firas Badin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Firas Badin. The network helps show where Firas Badin may publish in the future.

Co-authorship network of co-authors of Firas Badin

This figure shows the co-authorship network connecting the top 25 collaborators of Firas Badin. A scholar is included among the top collaborators of Firas Badin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Firas Badin. Firas Badin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jänne, Pasi A., Willemijn S.M.E. Theelen, Marina Chiara Garassino, et al.. (2025). First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.. Journal of Clinical Oncology. 43(16_suppl). 8500–8500. 1 indexed citations
2.
Paz‐Ares, Luis, Óscar Juan, Enriqueta Felip, et al.. (2025). Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer. Future Oncology. 21(25). 3245–3257. 1 indexed citations
3.
4.
Badin, Firas. (2024). Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting. Cancer Treatment and Research Communications. 39. 100803–100803. 1 indexed citations
5.
Lammers, Philip E., Guozhen Liu, Stephen F. Madden, et al.. (2024). P1.13A.10 Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study. Journal of Thoracic Oncology. 19(10). S210–S211. 1 indexed citations
6.
O’Byrne, Kenneth J., Evan Popoff, Firas Badin, et al.. (2023). EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis. Journal of Thoracic Oncology. 18(11). S629–S630.
7.
Badin, Firas, et al.. (2023). Breast cancer quality of care in Syria: screening, diagnosis, and staging. BMC Cancer. 23(1). 1234–1234. 4 indexed citations
8.
Garassino, Marina Chiara, Willemijn S.M.E. Theelen, Robert M. Jotte, et al.. (2023). LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Annals of Oncology. 34. S1309–S1310. 37 indexed citations
9.
Patel, Munjal, et al.. (2023). P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis. Journal of Thoracic Oncology. 18(11). S381–S381. 1 indexed citations
10.
11.
Bauer, Hillevi, Jyothi U. Menon, Sudhir Unni, et al.. (2022). Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study. Oncotarget. 13(1). 257–270. 3 indexed citations
12.
Rolfo, Christian, Laurent Greillier, Rémi Veillon, et al.. (2021). 465 Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study. SHILAP Revista de lepidopterología. A494–A494. 2 indexed citations
13.
Wrangle, John, Mark M. Awad, Firas Badin, et al.. (2021). Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).. Journal of Clinical Oncology. 39(15_suppl). 2596–2596. 23 indexed citations
14.
Rolfo, Christian, Laurent Greillier, Rémi Veillon, et al.. (2021). Abstract CT104: Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety results of the INTR@PID LUNG 024 study. Cancer Research. 81(13_Supplement). CT104–CT104. 1 indexed citations
15.
Levy, Benjamin, Luis Paz‐Ares, Jaafar Bennouna, et al.. (2019). Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer. 20(3). e407–e412. 8 indexed citations
16.
Levy, Benjamin, Luis Paz‐Ares, Jaafar Bennouna, et al.. (2018). Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology. 36(15_suppl). TPS9117–TPS9117. 1 indexed citations
17.
18.
19.
Badin, Firas, Anne C. Chiang, William B. Fisher, et al.. (2016). Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.. Journal of Clinical Oncology. 34(15_suppl). e20092–e20092. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie Naigeon Breakdown of academic impact, for papers by Mohammad Atiq Breakdown of academic impact, for papers by W. Victoria Lai Breakdown of academic impact, for papers by Grygorii Ursol Breakdown of academic impact, for papers by Avi Spira Breakdown of academic impact, for papers by Deepti Venkatraman Breakdown of academic impact, for papers by Xu-Shan Sun Breakdown of academic impact, for papers by David Vicente Baz Breakdown of academic impact, for papers by Andrés Aguilar Breakdown of academic impact, for papers by H.Z. Turna
Rankless by CCL
2026